Our partner, AstraZenecaUS announced that ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved by the US FDA for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.

Genetic testing affects your children. Learn how Kerith spoke to her children about her positive BRCA test. Watch Kerith’s story: youtube.com/watch?v=p-M3c4…
AstraZenecaUS

Sharsheret stands with Israel and prays for lasting peace.

The CDC’s Div of Cancer Prevention & Control launched the My Family Health Portrait: Cancer app, that helps individuals collect their family’s history of cancer & learn their risk for breast, ovarian & colorectal cancers. The app is available on Google Play & the App Store.

Our partner @SeagenGlobal announces: Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

News from Sharsheret's partner AstraZeneca:
Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer.
ow.ly/2A7Y50OPETe

Congrats to Sharsheret's partner, GE HealthCare: the NCCN Guidelines now recommend F-18 fluoroestradiol (Cerianna) for ER+ positive mBC systemic staging workup. Read more: ow.ly/U3sE50OI2jf #Sharsheret #GEHealthCare #NCCN #F18fluoroestradiol #Cerianna

Congrats to our partner Pfizer Inc.: the U.S. FDA expanded the indication for IBRANCE® (palbociclib) to include its use in combination with an AI as initial endocrine-based therapy for the treatment of HR+/HER2- mBC, regardless of menopausal status.

Sharsheret's Young Professionals Circle Casino Night is back on 12/17 🃏

🎲 Join us for a fun and meaningful evening of casino games, raffle prizes, food and drinks.

Hurry! Prices go up on December 1st. 🎰

Register here: link.sharsheret.org/YPCasino

Click to watch as women w/ advanced cancer share inspirational stories, memories, feelings & advice ow.ly/EQ9G50LuL7t. This video series is part of the Living Legacies project made possible w/ generous support from Gilead Sciences & in partnership with Memories Live.

Genetic results impact your treatment plan. Learn how Marissa's positive BRCA1 test impacted her breast cancer diagnosis. Watch Marissa's story: youtube.com/watch?v=5-m_Xp…

The @sharsheretofficial BRCA Hereditary Cancer video series is made possible w/ support from @Astrazeneca.

In honor of #BreastCancerAwarenessMonth Sharsheret’s CEO Elana Silber joined Jill Biden for the launch of a series of roundtables with American Cancer Society. Sharsheret is doing such important work to support Jewish women living with breast and ovarian cancer.

This #BreastCancerAwarenessMonth , we’re honored to support the work of our grantee, Sharsheret, one of the nation’s leading Jewish cancer organizations.

Sharsheret goes to the The White House!
Sharsheret's CEO Elana Silber meets with leaders in the cancer community to launch Cancer Moonshot's National Roundtables on Breast and Cervical Cancer.
Follow along as we share snippets from this groundbreaking day.

In this month’s blog, Gissoo DeCotiis, Global Head of Advocacy & Strategic Relations, shares how advocacy groups are meeting the needs of the diverse #BreastCancer community: bit.ly/3CvCYsW @SHAREing Tigerlily Foundation Susan G. Komen Sharsheret Living Beyond Breast Cancer

Need tips for managing your work life and cancer diagnosis? Join us at @CancerandCareers virtual West Coast Conference on Work & Cancer cancerandcareers.org/en/westcoast #CACWestCoast

1 in 72 women will develop #ovariancancer in their lifetime. Schedule a free family conference call with our genetic counselor to see how your family history plays a role in your health.

💗Contact us at [email protected] for FREE genetics support. #ovariancancer awareness

If you have questions about hereditary cancer, Peggy is here to help. Please contact us at [email protected], or call/text Peggy at (201) 661-6867 for FREE genetics support.

💗 P.S. We also offer family conference calls.

Sharsheret partner Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation. Read more here: ow.ly/hknp50KI5a8

Moms impacted by breast cancer are feeling desperate and invisible during the infant formula shortage. Living Beyond Breast Cancer recognizes their voices and struggles in this compelling article: lbbc.org/news-opinion/i…